Global Cancer Hormone Therapy Drugs Market

Cancer Hormone Therapy Drugs Comprehensive Study by Application (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine Cancer, Other Cancer Treatments), Drug (Anti-Estrogen Drugs, Aromatase Inhibitors, Antiandrogens, Androgen Synthesis Inhibitors, LHRH Drugs, Other), End Users (Doctors, Healthcare Practitioners, Laboratory Assistants, Medical Students, Others), Distribution Channel (Online, Offline, Specialty Stores, Pharmacy Shops) Players and Region - Global Market Outlook to 2028

Cancer Hormone Therapy Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cancer hormone therapy is a type of systemic therapy also known as hormonal therapy hormone therapy. It is not a specific treatment for the body the drugs travel throughout the body and inhibit the growth of cancer cells may block the hormones from the body to steady the rate or stop the growth of cancer cells. Hormones are the chemical messenger of the body situated in glands such as the thyroid, pancreas, and ovaries in women and testes in men. It does not work for all cancers. It is not like surgery or radiation therapy are considered local treatments or specific treatment it works in the whole body for inhibition of cancer cells.This growth is primarily driven by Increasing No of Cancer Patients Worldwide .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitK Units
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Amgen (United States), Pfizer (United States), Bristol Myers Squibb (United States), Johnson & Johnson (United States), Pharmacyclics (United States), Merck & Co (United States), Roche (Switzerland), Celgene (United States), Eli Lilly (United States) and Novartis (Switzerland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 13th January 2020, Amgen announces a merger to expand molecular testing for patients with non-small cell lung cancer. It is a strategic collaboration with leading diagnostic companies. It will initially focus on CDx tests for non-small cell lung cancer but allow for further development of the diagnostic tests for Amgen's other oncology clinical development programs.
On 4th February 2020, BioMotiv and Bristol-Myers Squibb announced the introduced the Anteros Pharmaceuticals. A biotechnological company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.Increasing no cancer patients increasing demand for different drugs in the market. The new drug discovery takes time as well as cost which only possible for top MNCs. The drugs effective, as well as cost-efficient aspects, are more appreciated in the market. The top companies are from the United States who are leading in the market. Mergers and acquisitions are also options for firms to rule the market.

Regulatory Insights:
In December 2019, FDA approved Pfizer, Astella’s Prostate cancer therapy Xtandi expanded label. The drug applied for the treatment of patients with metastatic hormone-sensitive prostate cancer, a form of prostate cancer that spreads to other parts of the body.

Influencing Trend:
Hormone Therapy, a Highly Effective Breast Cancer Treatment over Chemotherapy

Market Growth Drivers:
Increasing No of Cancer Patients Worldwide and Growing Usage because of its Cost-Effectiveness as Compare to Chemo Therapy

Challenges:
Long Process for New Drug Development and High Cost, Expensive Procedure and Harmful Effects of Chemotherapy are More Impermanent than Hormone therapy

Restraints:
Side Effects such as Tiredness, Menopausal Symptoms, Hair Thinning Muscle and Bone Changes, Weight Gain, Headaches, Memory Problems and Time Consuming Process to Show Benefits, Takes a Few Weeks for Initial Benefits

Opportunities:
Cancer is the Second Leading Cause of Death Globally, Responsible for High Number of Deaths According To WHO and Growing Clinical Research Studies for New Drugs on Hormonal Therapy

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Cancer Hormone Therapy Drugs Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Cancer Hormone Therapy Drugs Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Cancer Hormone Therapy Drugs players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Cancer Hormone Therapy Drugs Study Sheds Light on
— The Cancer Hormone Therapy Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cancer Hormone Therapy Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cancer Hormone Therapy Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Treat Prostate Cancer
  • Breast Cancers
  • Endometrial Cancer
  • Uterine Cancer
  • Other Cancer Treatments
By Drug
  • Anti-Estrogen Drugs
  • Aromatase Inhibitors
  • Antiandrogens
  • Androgen Synthesis Inhibitors
  • LHRH Drugs
  • Other

By End Users
  • Doctors
  • Healthcare Practitioners
  • Laboratory Assistants
  • Medical Students
  • Others

By Distribution Channel
  • Online
  • Offline
  • Specialty Stores
  • Pharmacy Shops

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing No of Cancer Patients Worldwide
      • 3.2.2. Growing Usage because of its Cost-Effectiveness as Compare to Chemo Therapy
    • 3.3. Market Challenges
      • 3.3.1. Long Process for New Drug Development and High Cost, Expensive Procedure
      • 3.3.2. Harmful Effects of Chemotherapy are More Impermanent than Hormone therapy
    • 3.4. Market Trends
      • 3.4.1. Hormone Therapy, a Highly Effective Breast Cancer Treatment over Chemotherapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Hormone Therapy Drugs, by Application, Drug, End Users, Distribution Channel and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Hormone Therapy Drugs (Value)
      • 5.2.1. Global Cancer Hormone Therapy Drugs by: Application (Value)
        • 5.2.1.1. Treat Prostate Cancer
        • 5.2.1.2. Breast Cancers
        • 5.2.1.3. Endometrial Cancer
        • 5.2.1.4. Uterine Cancer
        • 5.2.1.5. Other Cancer Treatments
      • 5.2.2. Global Cancer Hormone Therapy Drugs by: Drug (Value)
        • 5.2.2.1. Anti-Estrogen Drugs
        • 5.2.2.2. Aromatase Inhibitors
        • 5.2.2.3. Antiandrogens
        • 5.2.2.4. Androgen Synthesis Inhibitors
        • 5.2.2.5. LHRH Drugs
        • 5.2.2.6. Other
      • 5.2.3. Global Cancer Hormone Therapy Drugs by: End Users (Value)
        • 5.2.3.1. Doctors
        • 5.2.3.2. Healthcare Practitioners
        • 5.2.3.3. Laboratory Assistants
        • 5.2.3.4. Medical Students
        • 5.2.3.5. Others
      • 5.2.4. Global Cancer Hormone Therapy Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
        • 5.2.4.3. Specialty Stores
        • 5.2.4.4. Pharmacy Shops
      • 5.2.5. Global Cancer Hormone Therapy Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cancer Hormone Therapy Drugs (Volume)
      • 5.3.1. Global Cancer Hormone Therapy Drugs by: Application (Volume)
        • 5.3.1.1. Treat Prostate Cancer
        • 5.3.1.2. Breast Cancers
        • 5.3.1.3. Endometrial Cancer
        • 5.3.1.4. Uterine Cancer
        • 5.3.1.5. Other Cancer Treatments
      • 5.3.2. Global Cancer Hormone Therapy Drugs by: Drug (Volume)
        • 5.3.2.1. Anti-Estrogen Drugs
        • 5.3.2.2. Aromatase Inhibitors
        • 5.3.2.3. Antiandrogens
        • 5.3.2.4. Androgen Synthesis Inhibitors
        • 5.3.2.5. LHRH Drugs
        • 5.3.2.6. Other
      • 5.3.3. Global Cancer Hormone Therapy Drugs by: End Users (Volume)
        • 5.3.3.1. Doctors
        • 5.3.3.2. Healthcare Practitioners
        • 5.3.3.3. Laboratory Assistants
        • 5.3.3.4. Medical Students
        • 5.3.3.5. Others
      • 5.3.4. Global Cancer Hormone Therapy Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Online
        • 5.3.4.2. Offline
        • 5.3.4.3. Specialty Stores
        • 5.3.4.4. Pharmacy Shops
      • 5.3.5. Global Cancer Hormone Therapy Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Cancer Hormone Therapy Drugs (Price)
  • 6. Cancer Hormone Therapy Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pharmacyclics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Hormone Therapy Drugs Sale, by Application, Drug, End Users, Distribution Channel and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Hormone Therapy Drugs (Value)
      • 7.2.1. Global Cancer Hormone Therapy Drugs by: Application (Value)
        • 7.2.1.1. Treat Prostate Cancer
        • 7.2.1.2. Breast Cancers
        • 7.2.1.3. Endometrial Cancer
        • 7.2.1.4. Uterine Cancer
        • 7.2.1.5. Other Cancer Treatments
      • 7.2.2. Global Cancer Hormone Therapy Drugs by: Drug (Value)
        • 7.2.2.1. Anti-Estrogen Drugs
        • 7.2.2.2. Aromatase Inhibitors
        • 7.2.2.3. Antiandrogens
        • 7.2.2.4. Androgen Synthesis Inhibitors
        • 7.2.2.5. LHRH Drugs
        • 7.2.2.6. Other
      • 7.2.3. Global Cancer Hormone Therapy Drugs by: End Users (Value)
        • 7.2.3.1. Doctors
        • 7.2.3.2. Healthcare Practitioners
        • 7.2.3.3. Laboratory Assistants
        • 7.2.3.4. Medical Students
        • 7.2.3.5. Others
      • 7.2.4. Global Cancer Hormone Therapy Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
        • 7.2.4.3. Specialty Stores
        • 7.2.4.4. Pharmacy Shops
      • 7.2.5. Global Cancer Hormone Therapy Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cancer Hormone Therapy Drugs (Volume)
      • 7.3.1. Global Cancer Hormone Therapy Drugs by: Application (Volume)
        • 7.3.1.1. Treat Prostate Cancer
        • 7.3.1.2. Breast Cancers
        • 7.3.1.3. Endometrial Cancer
        • 7.3.1.4. Uterine Cancer
        • 7.3.1.5. Other Cancer Treatments
      • 7.3.2. Global Cancer Hormone Therapy Drugs by: Drug (Volume)
        • 7.3.2.1. Anti-Estrogen Drugs
        • 7.3.2.2. Aromatase Inhibitors
        • 7.3.2.3. Antiandrogens
        • 7.3.2.4. Androgen Synthesis Inhibitors
        • 7.3.2.5. LHRH Drugs
        • 7.3.2.6. Other
      • 7.3.3. Global Cancer Hormone Therapy Drugs by: End Users (Volume)
        • 7.3.3.1. Doctors
        • 7.3.3.2. Healthcare Practitioners
        • 7.3.3.3. Laboratory Assistants
        • 7.3.3.4. Medical Students
        • 7.3.3.5. Others
      • 7.3.4. Global Cancer Hormone Therapy Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Online
        • 7.3.4.2. Offline
        • 7.3.4.3. Specialty Stores
        • 7.3.4.4. Pharmacy Shops
      • 7.3.5. Global Cancer Hormone Therapy Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Cancer Hormone Therapy Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Hormone Therapy Drugs: by Application(USD Million)
  • Table 2. Cancer Hormone Therapy Drugs Treat Prostate Cancer , by Region USD Million (2017-2022)
  • Table 3. Cancer Hormone Therapy Drugs Breast Cancers , by Region USD Million (2017-2022)
  • Table 4. Cancer Hormone Therapy Drugs Endometrial Cancer , by Region USD Million (2017-2022)
  • Table 5. Cancer Hormone Therapy Drugs Uterine Cancer , by Region USD Million (2017-2022)
  • Table 6. Cancer Hormone Therapy Drugs Other Cancer Treatments , by Region USD Million (2017-2022)
  • Table 7. Cancer Hormone Therapy Drugs: by Drug(USD Million)
  • Table 8. Cancer Hormone Therapy Drugs Anti-Estrogen Drugs , by Region USD Million (2017-2022)
  • Table 9. Cancer Hormone Therapy Drugs Aromatase Inhibitors , by Region USD Million (2017-2022)
  • Table 10. Cancer Hormone Therapy Drugs Antiandrogens , by Region USD Million (2017-2022)
  • Table 11. Cancer Hormone Therapy Drugs Androgen Synthesis Inhibitors , by Region USD Million (2017-2022)
  • Table 12. Cancer Hormone Therapy Drugs LHRH Drugs , by Region USD Million (2017-2022)
  • Table 13. Cancer Hormone Therapy Drugs Other , by Region USD Million (2017-2022)
  • Table 14. Cancer Hormone Therapy Drugs: by End Users(USD Million)
  • Table 15. Cancer Hormone Therapy Drugs Doctors , by Region USD Million (2017-2022)
  • Table 16. Cancer Hormone Therapy Drugs Healthcare Practitioners , by Region USD Million (2017-2022)
  • Table 17. Cancer Hormone Therapy Drugs Laboratory Assistants , by Region USD Million (2017-2022)
  • Table 18. Cancer Hormone Therapy Drugs Medical Students , by Region USD Million (2017-2022)
  • Table 19. Cancer Hormone Therapy Drugs Others , by Region USD Million (2017-2022)
  • Table 20. Cancer Hormone Therapy Drugs: by Distribution Channel(USD Million)
  • Table 21. Cancer Hormone Therapy Drugs Online , by Region USD Million (2017-2022)
  • Table 22. Cancer Hormone Therapy Drugs Offline , by Region USD Million (2017-2022)
  • Table 23. Cancer Hormone Therapy Drugs Specialty Stores , by Region USD Million (2017-2022)
  • Table 24. Cancer Hormone Therapy Drugs Pharmacy Shops , by Region USD Million (2017-2022)
  • Table 25. South America Cancer Hormone Therapy Drugs, by Country USD Million (2017-2022)
  • Table 26. South America Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 27. South America Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 28. South America Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 29. South America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 30. Brazil Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 31. Brazil Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 32. Brazil Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 33. Brazil Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 34. Argentina Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 35. Argentina Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 36. Argentina Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 37. Argentina Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 38. Rest of South America Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 39. Rest of South America Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 40. Rest of South America Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 41. Rest of South America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 42. Asia Pacific Cancer Hormone Therapy Drugs, by Country USD Million (2017-2022)
  • Table 43. Asia Pacific Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 44. Asia Pacific Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 45. Asia Pacific Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 46. Asia Pacific Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 47. China Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 48. China Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 49. China Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 50. China Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 51. Japan Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 52. Japan Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 53. Japan Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 54. Japan Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 55. India Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 56. India Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 57. India Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 58. India Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 59. South Korea Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 60. South Korea Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 61. South Korea Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 62. South Korea Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 63. Taiwan Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 64. Taiwan Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 65. Taiwan Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 66. Taiwan Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 67. Australia Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 68. Australia Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 69. Australia Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 70. Australia Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 72. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 73. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 74. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 75. Europe Cancer Hormone Therapy Drugs, by Country USD Million (2017-2022)
  • Table 76. Europe Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 77. Europe Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 78. Europe Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 79. Europe Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 80. Germany Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 81. Germany Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 82. Germany Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 83. Germany Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 84. France Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 85. France Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 86. France Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 87. France Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 88. Italy Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 89. Italy Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 90. Italy Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 91. Italy Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 92. United Kingdom Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 93. United Kingdom Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 94. United Kingdom Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 95. United Kingdom Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 96. Netherlands Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 97. Netherlands Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 98. Netherlands Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 99. Netherlands Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 100. Rest of Europe Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 101. Rest of Europe Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 102. Rest of Europe Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 103. Rest of Europe Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 104. MEA Cancer Hormone Therapy Drugs, by Country USD Million (2017-2022)
  • Table 105. MEA Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 106. MEA Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 107. MEA Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 108. MEA Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 109. Middle East Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 110. Middle East Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 111. Middle East Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 112. Middle East Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 113. Africa Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 114. Africa Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 115. Africa Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 116. Africa Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 117. North America Cancer Hormone Therapy Drugs, by Country USD Million (2017-2022)
  • Table 118. North America Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 119. North America Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 120. North America Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 121. North America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 122. United States Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 123. United States Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 124. United States Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 125. United States Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 126. Canada Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 127. Canada Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 128. Canada Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 129. Canada Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 130. Mexico Cancer Hormone Therapy Drugs, by Application USD Million (2017-2022)
  • Table 131. Mexico Cancer Hormone Therapy Drugs, by Drug USD Million (2017-2022)
  • Table 132. Mexico Cancer Hormone Therapy Drugs, by End Users USD Million (2017-2022)
  • Table 133. Mexico Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 134. Cancer Hormone Therapy Drugs Sales: by Application(K Units)
  • Table 135. Cancer Hormone Therapy Drugs Sales Treat Prostate Cancer , by Region K Units (2017-2022)
  • Table 136. Cancer Hormone Therapy Drugs Sales Breast Cancers , by Region K Units (2017-2022)
  • Table 137. Cancer Hormone Therapy Drugs Sales Endometrial Cancer , by Region K Units (2017-2022)
  • Table 138. Cancer Hormone Therapy Drugs Sales Uterine Cancer , by Region K Units (2017-2022)
  • Table 139. Cancer Hormone Therapy Drugs Sales Other Cancer Treatments , by Region K Units (2017-2022)
  • Table 140. Cancer Hormone Therapy Drugs Sales: by Drug(K Units)
  • Table 141. Cancer Hormone Therapy Drugs Sales Anti-Estrogen Drugs , by Region K Units (2017-2022)
  • Table 142. Cancer Hormone Therapy Drugs Sales Aromatase Inhibitors , by Region K Units (2017-2022)
  • Table 143. Cancer Hormone Therapy Drugs Sales Antiandrogens , by Region K Units (2017-2022)
  • Table 144. Cancer Hormone Therapy Drugs Sales Androgen Synthesis Inhibitors , by Region K Units (2017-2022)
  • Table 145. Cancer Hormone Therapy Drugs Sales LHRH Drugs , by Region K Units (2017-2022)
  • Table 146. Cancer Hormone Therapy Drugs Sales Other , by Region K Units (2017-2022)
  • Table 147. Cancer Hormone Therapy Drugs Sales: by End Users(K Units)
  • Table 148. Cancer Hormone Therapy Drugs Sales Doctors , by Region K Units (2017-2022)
  • Table 149. Cancer Hormone Therapy Drugs Sales Healthcare Practitioners , by Region K Units (2017-2022)
  • Table 150. Cancer Hormone Therapy Drugs Sales Laboratory Assistants , by Region K Units (2017-2022)
  • Table 151. Cancer Hormone Therapy Drugs Sales Medical Students , by Region K Units (2017-2022)
  • Table 152. Cancer Hormone Therapy Drugs Sales Others , by Region K Units (2017-2022)
  • Table 153. Cancer Hormone Therapy Drugs Sales: by Distribution Channel(K Units)
  • Table 154. Cancer Hormone Therapy Drugs Sales Online , by Region K Units (2017-2022)
  • Table 155. Cancer Hormone Therapy Drugs Sales Offline , by Region K Units (2017-2022)
  • Table 156. Cancer Hormone Therapy Drugs Sales Specialty Stores , by Region K Units (2017-2022)
  • Table 157. Cancer Hormone Therapy Drugs Sales Pharmacy Shops , by Region K Units (2017-2022)
  • Table 158. South America Cancer Hormone Therapy Drugs Sales, by Country K Units (2017-2022)
  • Table 159. South America Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 160. South America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 161. South America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 162. South America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 163. Brazil Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 164. Brazil Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 165. Brazil Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 166. Brazil Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 167. Argentina Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 168. Argentina Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 169. Argentina Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 170. Argentina Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 171. Rest of South America Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 172. Rest of South America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 173. Rest of South America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 174. Rest of South America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 175. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Country K Units (2017-2022)
  • Table 176. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 177. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 178. Asia Pacific Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 179. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 180. China Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 181. China Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 182. China Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 183. China Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 184. Japan Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 185. Japan Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 186. Japan Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 187. Japan Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 188. India Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 189. India Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 190. India Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 191. India Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 192. South Korea Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 193. South Korea Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 194. South Korea Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 195. South Korea Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 196. Taiwan Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 197. Taiwan Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 198. Taiwan Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 199. Taiwan Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 200. Australia Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 201. Australia Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 202. Australia Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 203. Australia Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 204. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 205. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 206. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 207. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 208. Europe Cancer Hormone Therapy Drugs Sales, by Country K Units (2017-2022)
  • Table 209. Europe Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 210. Europe Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 211. Europe Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 212. Europe Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 213. Germany Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 214. Germany Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 215. Germany Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 216. Germany Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 217. France Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 218. France Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 219. France Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 220. France Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 221. Italy Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 222. Italy Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 223. Italy Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 224. Italy Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 225. United Kingdom Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 226. United Kingdom Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 227. United Kingdom Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 228. United Kingdom Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 229. Netherlands Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 230. Netherlands Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 231. Netherlands Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 232. Netherlands Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 233. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 234. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 235. Rest of Europe Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 236. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 237. MEA Cancer Hormone Therapy Drugs Sales, by Country K Units (2017-2022)
  • Table 238. MEA Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 239. MEA Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 240. MEA Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 241. MEA Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 242. Middle East Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 243. Middle East Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 244. Middle East Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 245. Middle East Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 246. Africa Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 247. Africa Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 248. Africa Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 249. Africa Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 250. North America Cancer Hormone Therapy Drugs Sales, by Country K Units (2017-2022)
  • Table 251. North America Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 252. North America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 253. North America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 254. North America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 255. United States Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 256. United States Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 257. United States Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 258. United States Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 259. Canada Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 260. Canada Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 261. Canada Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 262. Canada Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 263. Mexico Cancer Hormone Therapy Drugs Sales, by Application K Units (2017-2022)
  • Table 264. Mexico Cancer Hormone Therapy Drugs Sales, by Drug K Units (2017-2022)
  • Table 265. Mexico Cancer Hormone Therapy Drugs Sales, by End Users K Units (2017-2022)
  • Table 266. Mexico Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Cancer Hormone Therapy Drugs: by Application(USD Million)
  • Table 278. Cancer Hormone Therapy Drugs Treat Prostate Cancer , by Region USD Million (2023-2028)
  • Table 279. Cancer Hormone Therapy Drugs Breast Cancers , by Region USD Million (2023-2028)
  • Table 280. Cancer Hormone Therapy Drugs Endometrial Cancer , by Region USD Million (2023-2028)
  • Table 281. Cancer Hormone Therapy Drugs Uterine Cancer , by Region USD Million (2023-2028)
  • Table 282. Cancer Hormone Therapy Drugs Other Cancer Treatments , by Region USD Million (2023-2028)
  • Table 283. Cancer Hormone Therapy Drugs: by Drug(USD Million)
  • Table 284. Cancer Hormone Therapy Drugs Anti-Estrogen Drugs , by Region USD Million (2023-2028)
  • Table 285. Cancer Hormone Therapy Drugs Aromatase Inhibitors , by Region USD Million (2023-2028)
  • Table 286. Cancer Hormone Therapy Drugs Antiandrogens , by Region USD Million (2023-2028)
  • Table 287. Cancer Hormone Therapy Drugs Androgen Synthesis Inhibitors , by Region USD Million (2023-2028)
  • Table 288. Cancer Hormone Therapy Drugs LHRH Drugs , by Region USD Million (2023-2028)
  • Table 289. Cancer Hormone Therapy Drugs Other , by Region USD Million (2023-2028)
  • Table 290. Cancer Hormone Therapy Drugs: by End Users(USD Million)
  • Table 291. Cancer Hormone Therapy Drugs Doctors , by Region USD Million (2023-2028)
  • Table 292. Cancer Hormone Therapy Drugs Healthcare Practitioners , by Region USD Million (2023-2028)
  • Table 293. Cancer Hormone Therapy Drugs Laboratory Assistants , by Region USD Million (2023-2028)
  • Table 294. Cancer Hormone Therapy Drugs Medical Students , by Region USD Million (2023-2028)
  • Table 295. Cancer Hormone Therapy Drugs Others , by Region USD Million (2023-2028)
  • Table 296. Cancer Hormone Therapy Drugs: by Distribution Channel(USD Million)
  • Table 297. Cancer Hormone Therapy Drugs Online , by Region USD Million (2023-2028)
  • Table 298. Cancer Hormone Therapy Drugs Offline , by Region USD Million (2023-2028)
  • Table 299. Cancer Hormone Therapy Drugs Specialty Stores , by Region USD Million (2023-2028)
  • Table 300. Cancer Hormone Therapy Drugs Pharmacy Shops , by Region USD Million (2023-2028)
  • Table 301. South America Cancer Hormone Therapy Drugs, by Country USD Million (2023-2028)
  • Table 302. South America Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 303. South America Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 304. South America Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 305. South America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 306. Brazil Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 307. Brazil Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 308. Brazil Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 309. Brazil Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 310. Argentina Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 311. Argentina Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 312. Argentina Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 313. Argentina Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 314. Rest of South America Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 315. Rest of South America Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 316. Rest of South America Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 317. Rest of South America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 318. Asia Pacific Cancer Hormone Therapy Drugs, by Country USD Million (2023-2028)
  • Table 319. Asia Pacific Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 320. Asia Pacific Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 321. Asia Pacific Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 322. Asia Pacific Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 323. China Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 324. China Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 325. China Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 326. China Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 327. Japan Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 328. Japan Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 329. Japan Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 330. Japan Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 331. India Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 332. India Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 333. India Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 334. India Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 335. South Korea Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 336. South Korea Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 337. South Korea Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 338. South Korea Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 339. Taiwan Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 340. Taiwan Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 341. Taiwan Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 342. Taiwan Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 343. Australia Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 344. Australia Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 345. Australia Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 346. Australia Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 347. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 348. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 349. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 350. Rest of Asia-Pacific Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 351. Europe Cancer Hormone Therapy Drugs, by Country USD Million (2023-2028)
  • Table 352. Europe Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 353. Europe Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 354. Europe Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 355. Europe Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 356. Germany Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 357. Germany Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 358. Germany Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 359. Germany Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 360. France Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 361. France Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 362. France Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 363. France Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 364. Italy Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 365. Italy Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 366. Italy Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 367. Italy Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 368. United Kingdom Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 369. United Kingdom Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 370. United Kingdom Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 371. United Kingdom Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 372. Netherlands Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 373. Netherlands Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 374. Netherlands Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 375. Netherlands Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 376. Rest of Europe Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 377. Rest of Europe Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 378. Rest of Europe Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 379. Rest of Europe Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 380. MEA Cancer Hormone Therapy Drugs, by Country USD Million (2023-2028)
  • Table 381. MEA Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 382. MEA Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 383. MEA Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 384. MEA Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 385. Middle East Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 386. Middle East Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 387. Middle East Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 388. Middle East Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 389. Africa Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 390. Africa Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 391. Africa Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 392. Africa Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 393. North America Cancer Hormone Therapy Drugs, by Country USD Million (2023-2028)
  • Table 394. North America Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 395. North America Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 396. North America Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 397. North America Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 398. United States Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 399. United States Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 400. United States Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 401. United States Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 402. Canada Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 403. Canada Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 404. Canada Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 405. Canada Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 406. Mexico Cancer Hormone Therapy Drugs, by Application USD Million (2023-2028)
  • Table 407. Mexico Cancer Hormone Therapy Drugs, by Drug USD Million (2023-2028)
  • Table 408. Mexico Cancer Hormone Therapy Drugs, by End Users USD Million (2023-2028)
  • Table 409. Mexico Cancer Hormone Therapy Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 410. Cancer Hormone Therapy Drugs Sales: by Application(K Units)
  • Table 411. Cancer Hormone Therapy Drugs Sales Treat Prostate Cancer , by Region K Units (2023-2028)
  • Table 412. Cancer Hormone Therapy Drugs Sales Breast Cancers , by Region K Units (2023-2028)
  • Table 413. Cancer Hormone Therapy Drugs Sales Endometrial Cancer , by Region K Units (2023-2028)
  • Table 414. Cancer Hormone Therapy Drugs Sales Uterine Cancer , by Region K Units (2023-2028)
  • Table 415. Cancer Hormone Therapy Drugs Sales Other Cancer Treatments , by Region K Units (2023-2028)
  • Table 416. Cancer Hormone Therapy Drugs Sales: by Drug(K Units)
  • Table 417. Cancer Hormone Therapy Drugs Sales Anti-Estrogen Drugs , by Region K Units (2023-2028)
  • Table 418. Cancer Hormone Therapy Drugs Sales Aromatase Inhibitors , by Region K Units (2023-2028)
  • Table 419. Cancer Hormone Therapy Drugs Sales Antiandrogens , by Region K Units (2023-2028)
  • Table 420. Cancer Hormone Therapy Drugs Sales Androgen Synthesis Inhibitors , by Region K Units (2023-2028)
  • Table 421. Cancer Hormone Therapy Drugs Sales LHRH Drugs , by Region K Units (2023-2028)
  • Table 422. Cancer Hormone Therapy Drugs Sales Other , by Region K Units (2023-2028)
  • Table 423. Cancer Hormone Therapy Drugs Sales: by End Users(K Units)
  • Table 424. Cancer Hormone Therapy Drugs Sales Doctors , by Region K Units (2023-2028)
  • Table 425. Cancer Hormone Therapy Drugs Sales Healthcare Practitioners , by Region K Units (2023-2028)
  • Table 426. Cancer Hormone Therapy Drugs Sales Laboratory Assistants , by Region K Units (2023-2028)
  • Table 427. Cancer Hormone Therapy Drugs Sales Medical Students , by Region K Units (2023-2028)
  • Table 428. Cancer Hormone Therapy Drugs Sales Others , by Region K Units (2023-2028)
  • Table 429. Cancer Hormone Therapy Drugs Sales: by Distribution Channel(K Units)
  • Table 430. Cancer Hormone Therapy Drugs Sales Online , by Region K Units (2023-2028)
  • Table 431. Cancer Hormone Therapy Drugs Sales Offline , by Region K Units (2023-2028)
  • Table 432. Cancer Hormone Therapy Drugs Sales Specialty Stores , by Region K Units (2023-2028)
  • Table 433. Cancer Hormone Therapy Drugs Sales Pharmacy Shops , by Region K Units (2023-2028)
  • Table 434. South America Cancer Hormone Therapy Drugs Sales, by Country K Units (2023-2028)
  • Table 435. South America Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 436. South America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 437. South America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 438. South America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 439. Brazil Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 440. Brazil Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 441. Brazil Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 442. Brazil Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 443. Argentina Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 444. Argentina Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 445. Argentina Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 446. Argentina Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 447. Rest of South America Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 448. Rest of South America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 449. Rest of South America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 450. Rest of South America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 451. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Country K Units (2023-2028)
  • Table 452. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 453. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 454. Asia Pacific Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 455. Asia Pacific Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 456. China Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 457. China Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 458. China Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 459. China Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 460. Japan Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 461. Japan Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 462. Japan Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 463. Japan Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 464. India Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 465. India Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 466. India Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 467. India Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 468. South Korea Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 469. South Korea Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 470. South Korea Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 471. South Korea Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 472. Taiwan Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 473. Taiwan Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 474. Taiwan Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 475. Taiwan Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 476. Australia Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 477. Australia Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 478. Australia Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 479. Australia Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 480. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 481. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 482. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 483. Rest of Asia-Pacific Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 484. Europe Cancer Hormone Therapy Drugs Sales, by Country K Units (2023-2028)
  • Table 485. Europe Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 486. Europe Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 487. Europe Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 488. Europe Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 489. Germany Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 490. Germany Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 491. Germany Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 492. Germany Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 493. France Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 494. France Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 495. France Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 496. France Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 497. Italy Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 498. Italy Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 499. Italy Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 500. Italy Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 501. United Kingdom Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 502. United Kingdom Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 503. United Kingdom Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 504. United Kingdom Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 505. Netherlands Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 506. Netherlands Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 507. Netherlands Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 508. Netherlands Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 509. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 510. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 511. Rest of Europe Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 512. Rest of Europe Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 513. MEA Cancer Hormone Therapy Drugs Sales, by Country K Units (2023-2028)
  • Table 514. MEA Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 515. MEA Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 516. MEA Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 517. MEA Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 518. Middle East Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 519. Middle East Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 520. Middle East Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 521. Middle East Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 522. Africa Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 523. Africa Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 524. Africa Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 525. Africa Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 526. North America Cancer Hormone Therapy Drugs Sales, by Country K Units (2023-2028)
  • Table 527. North America Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 528. North America Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 529. North America Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 530. North America Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 531. United States Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 532. United States Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 533. United States Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 534. United States Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 535. Canada Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 536. Canada Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 537. Canada Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 538. Canada Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 539. Mexico Cancer Hormone Therapy Drugs Sales, by Application K Units (2023-2028)
  • Table 540. Mexico Cancer Hormone Therapy Drugs Sales, by Drug K Units (2023-2028)
  • Table 541. Mexico Cancer Hormone Therapy Drugs Sales, by End Users K Units (2023-2028)
  • Table 542. Mexico Cancer Hormone Therapy Drugs Sales, by Distribution Channel K Units (2023-2028)
  • Table 543. Research Programs/Design for This Report
  • Table 544. Key Data Information from Secondary Sources
  • Table 545. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Hormone Therapy Drugs: by Application USD Million (2017-2022)
  • Figure 5. Global Cancer Hormone Therapy Drugs: by Drug USD Million (2017-2022)
  • Figure 6. Global Cancer Hormone Therapy Drugs: by End Users USD Million (2017-2022)
  • Figure 7. Global Cancer Hormone Therapy Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 8. South America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 9. Asia Pacific Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 10. Europe Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 11. MEA Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 12. North America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 13. Global Cancer Hormone Therapy Drugs: by Application K Units (2017-2022)
  • Figure 14. Global Cancer Hormone Therapy Drugs: by Drug K Units (2017-2022)
  • Figure 15. Global Cancer Hormone Therapy Drugs: by End Users K Units (2017-2022)
  • Figure 16. Global Cancer Hormone Therapy Drugs: by Distribution Channel K Units (2017-2022)
  • Figure 17. South America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 18. Asia Pacific Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 19. Europe Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 20. MEA Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 21. North America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 22. Global Cancer Hormone Therapy Drugs share by Players 2022 (%)
  • Figure 23. Global Cancer Hormone Therapy Drugs share by Players (Top 3) 2022(%)
  • Figure 24. Global Cancer Hormone Therapy Drugs share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen (United States) Revenue: by Geography 2022
  • Figure 28. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer (United States) Revenue: by Geography 2022
  • Figure 30. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 32. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 34. Pharmacyclics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Pharmacyclics (United States) Revenue: by Geography 2022
  • Figure 36. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 37. Merck & Co (United States) Revenue: by Geography 2022
  • Figure 38. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 40. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 41. Celgene (United States) Revenue: by Geography 2022
  • Figure 42. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 43. Eli Lilly (United States) Revenue: by Geography 2022
  • Figure 44. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 45. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 46. Global Cancer Hormone Therapy Drugs: by Application USD Million (2023-2028)
  • Figure 47. Global Cancer Hormone Therapy Drugs: by Drug USD Million (2023-2028)
  • Figure 48. Global Cancer Hormone Therapy Drugs: by End Users USD Million (2023-2028)
  • Figure 49. Global Cancer Hormone Therapy Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 50. South America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 51. Asia Pacific Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 52. Europe Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 53. MEA Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 54. North America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 55. Global Cancer Hormone Therapy Drugs: by Application K Units (2023-2028)
  • Figure 56. Global Cancer Hormone Therapy Drugs: by Drug K Units (2023-2028)
  • Figure 57. Global Cancer Hormone Therapy Drugs: by End Users K Units (2023-2028)
  • Figure 58. Global Cancer Hormone Therapy Drugs: by Distribution Channel K Units (2023-2028)
  • Figure 59. South America Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 60. Asia Pacific Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 61. Europe Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 62. MEA Cancer Hormone Therapy Drugs Share (%), by Country
  • Figure 63. North America Cancer Hormone Therapy Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen (United States)
  • Pfizer (United States)
  • Bristol Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • Pharmacyclics (United States)
  • Merck & Co (United States)
  • Roche (Switzerland)
  • Celgene (United States)
  • Eli Lilly (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
AstraZeneca (United Kingdom) , Astellas Pharma (United States) , AbbVie (United States)
Select User Access Type

Key Highlights of Report


May 2023 226 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Hormone Therapy Drugs Market Quantitative research analysis
Global Cancer Hormone Therapy Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Cancer Hormone Therapy Drugs Market are Amgen (United States), Pfizer (United States), Bristol Myers Squibb (United States), Johnson & Johnson (United States), Pharmacyclics (United States), Merck & Co (United States), Roche (Switzerland), Celgene (United States), Eli Lilly (United States) and Novartis (Switzerland) etc.
Treat Prostate Cancer segment in Global market to hold robust market share owing to "Increasing No of Cancer Patients Worldwide ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Cancer Hormone Therapy Drugs market throughout the forecasted period.

Know More About Global Cancer Hormone Therapy Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Vitamin D Therapy Comprehensive Study by Type (Vitamin D3, Vitamin D2), Application (Pharmaceuticals, Functional Food & Beverages, Personal Care, Feed & Pet Food, Animal Feed, Pet Food, Supplements a...
$ 3750
Microneedle Drug Delivery Systems  Comprehensive Study by Type (Hollow Microneedle Technology, Solid Microneedle Technology, Dissolving Microneedles Technology), Application (Drug Delivery, Vaccine D...
$ 3750
Wound and Skin Infection Treatment Comprehensive Study by End Users (Hospital, Clinic, Household), Distribution Channels (Online {Company Website, E-Commerce Website}, Offline {Hospital Pharmacy, Med...
$ 3750
Coronary Drug Comprehensive Study by Type (Durable Polymer Drug-eluting Stents, Bioabsorbable Polymer Drug-eluting Stent, Other), Application (Coronary Heart Disease, Clinical), Distribution Channel ...
$ 3450
Pentazocine Comprehensive Study by Application (Postoperative pain, Chronic Pain, Obstetrics, Renal and biliary colic, Myocardial infarction, Intravenous anaesthesia and premedication, Others), Patie...
$ 3750
Thrombolytic Drug Comprehensive Study by Type (Tissue plasminogen activator (tPA), Streptokinase (SK), Urokinase (UK)), Application (Drug Treatment, Surgical Treatment, Other Treatment), Fibrin (Fibr...
$ 3650